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Abstract
Deep vein thrombosis and pulmonary embolism are a significant health care concern, representing
a major source of mortality and morbidity. In order to understand the pathophysiology of
thrombogenesis and thrombus resolution, animal models are necessary. Mouse models of venous
thrombosis contribute to our understanding of the initiation, propagation, and resolution of venous
thrombus, as well as allow for the evaluation of new pharmaceutical approaches to prophylaxis
and treatment of deep vein thrombosis. In this work we review the ferric chloride model, the
inferior vena cava ligation model, the inferior vena cava stenosis models, and the electrolytic
inferior vena cava model and compare their advantages and disadvantages.
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Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary
embolism, are a major source of morbidity and mortality worldwide. Recent research
estimates the incidence of venous thromboembolism in the United States alone at 900,000
per year, with a quarter of the cases resulting in fatality.1,2 In 2008, The Surgeon General’s
Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism, states “the
disease disproportionately affects older Americans, and we can expect more suffering and
more deaths in the future as the population ages—unless we do something about it.” This
document invited multiple stakeholders, including all areas of research and the health care
systems, to come together in a coordinated effort to reverse this dramatic projected trend.2
Animal models are fundamental to accomplishing this objective. Mouse models of DVT
constitute a unique biological environment in which investigators may evaluate not only the
biology behind DVT, but also new pharmaceutical approaches. Here we review the most
widely used mouse models to evaluate venous thrombogenesis and thrombus resolution.
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Impetus for Development of a Murine Model
Humans stand alone as the singular species with propensity to develop spontaneous DVT.
Because Virchow’s original description of a canine model, there has been interest in the
development of animal models of thrombosis to mimic the human condition.3 Initial labors
were directed toward development of large mammal models.4,5 The transgenic mouse era
led toward efforts to translate the existing models into the smaller rodent species. Mice are
amenable for the study of venous thrombosis and have the advantages of relatively low cost
and the availability of different genetically manipulated strains. However, important
differences to humans include body size, life span, genetic differences, and vessel size.
Nevertheless, mouse models have increased our understanding of venous thrombosis.
Applications in Mice
Studying the genetic defects in humans and mice is crucial in order to gain insight into
venous thrombosis. A fairly complete list of genetic deficiencies involved in human
bleeding disorders is known, but our knowledge regarding genetic factors related to the
increased propensity toward thrombosis remains incomplete.6 Sequencing of the mouse
genome has allowed physiological manipulation of gene addition (transgenic) and gene
deletion (knockout) mice, which has greatly increased our understanding of thrombotic
processes.7,8
Because, in most cases, it is not possible to obtain human samples from the site of DVT to
study the disease, it is advantageous for researchers to use animal models to investigate
DVT in a biological setting. The link between inflammation, innate immunity, and venous
thrombosis has recently been demonstrated through impaired venous thrombus resolution
via a non-MyD88 dependent toll-like receptor 9 pathway in mice undergoing venous
ligation.9 Similarly, multiple aspects of inflammation and venous thrombosis have been
derived from mouse models.10 The essential role of E-selectin in the pathogenicity of
antiphospholipid antibody syndrome was directly demonstrated by a mechanical femoral
vein injury in E-selectin knockout mice treated with antiphospholipid antibody syndrome
antibodies.11 However, these observations still need to be confirmed in patients.
The understanding of the biological events associated with venous thrombosis and their
manipulation by pharmacological agents is dependent on studying animal models. The
relative successes of recombinant tissue plasminogen activator, enoxaparin, hirudin, and
argatroban could not have been predicted without information gleaned from early preclinical
laboratory experiments with animals, nor the failures of other anticoagulant drugs that
appeared promising in in vitro studies but failed to live up to expectations.12–16 The use of
thrombosis models in rodents plays a crucial role in bridging the bench to bedside transition.
For example, primate studies are validating mouse studies that have suggested P-selectin
inhibitors are potential therapeutic agents in the prophylaxis and treatment of DVT.8,17,18
Acute Versus Chronic DVT in Mice
Mice have a short life span and high metabolic rate, compared to humans. Thus, events
occur faster in mice. Clinically, DVT in humans can be defined as acute, subacute and
chronic. In mice, acute DVT is defined, in terms of time, from thrombus induction up to 2 to
3 days. Beyond that time point, subacute DVT and chronic DVT occur. Neutrophil
migration occurs during the acute phase, and they are the main inflammatory cells in both
the vein wall and thrombus. A shifting between neutrophils and monocytes occurs by day 6.
After that, monocytes become the predominant inflammatory cells in both vein wall and
thrombus19 (Figure 1). In addition, fibrotic changes after DVT help us to understand stages
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of DVT in mice. Collagen deposition and tissue remodeling events, almost absent during
acute DVT, are present during the more chronic stages in both vein wall and thrombus.
Mouse models having long-term endpoints are suitable for the study of chronic DVT, with
remodeling of the vein wall similar to what is observed in the post-thrombotic
syndrome.4,20,21
Analytic Evaluative Methods
The mouse models presented in this review contribute to the understanding of the
pathophysiology at various stages of DVT. Large vessel models (mostly involving the IVC)
are used to explore both acute and chronic DVT.8,9,17,20,22–25 These models can be used to
measure various parameters, including thrombus formation, thrombus weights,8,9,17,20,22–25
vein wall inflammatory cell counts,20 perform immunohistochemistry,20 and stain for
fibrosis (Masson’s stain,9,20 Sirius Red stain). In addition, gene expression,20 protein levels
(ELISA,20,23 western blot), and protein activity (eg, measuring matrix metalloproteinases
using zymography)23 can be measured. In blood, microparticles, hematology, coagulation,
and markers of inflammation (interleukin-6, CCL2, interleukin-1, soluble P- and E-selectin,
etc.) can be studied.
Small Vein Models
Mechanical injury,26 endothelial stimulation,22,27–30 and photochemical injury31–37 are all
important models to study venous thrombosis. For example, leukocyte and platelet rolling
are studied in mesenteric venules stimulated with calcium ionophore A23187 using intravital
microscopy.27,38 These studies analyze events that occur within the vein over a short period
of time, helping to understand principles of thrombogenesis (acute thrombosis) but not long-
term consequences of thrombosis. However they will not be reviewed in the current work
because we are focusing on larger vein models.
Large Vein Models
Ferric Chloride Model—The ferric chloride model was initially developed over 20 years
ago with the intent to study arterial thrombosis in a rat model.39 Ferric chloride induced
thrombosis has been described in both microvascular28 and macrovascular models of mouse
venous thrombosis.40 The mouse is anesthetized, the IVC is exposed through a midline
incision, and the infrarenal surface cleared to the level of the iliolumbar veins. A 2-mm×4-
mm filter paper is presoaked in 3.5% FeCl3 solution and placed on the surface of the vein
for 2 to 3 minutes, then removed. Alternatively, microvascular thrombosis may be induced
with the application of 10% FeCl3 to mesenteric venules or internal jugular vein.28,41 The
resulting transmural vessel wall injury leads to the formation of occlusive thrombi.4 This
model reliably produces thrombi within minutes post injury. The size and speed of thrombus
formation is FeCl3 concentration/time of exposure dependent. In general, the resultant
venous thrombus is smaller than those produced by stasis. A disadvantage of this model is
the production of a transmural vein wall injury that mimics only a minority of clinical DVT
cases (Table).
IVC Ligation Model—This model provides a total stasis environment and results in the
most severe vein wall reaction to thrombosis of the models discussed.8,17,20,23 Studies in
rats suggest that after IVC ligation a combination of stasis-induced vein wall injury and
enhanced tissue factor expression in endothelial cells and leukocytes produce thrombosis.42
In this model, mice are anesthetized and a midline laparotomy is performed. The small
bowel is exteriorized and placed on a moistened gauze pad to the animal’s left. The
infrarenal IVC is identified and all side branches are ligated with nonreactive 7-0 Prolene
suture. Posterior venous branches are cauterized.23 A 7-0 Prolene suture is tied down on the
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IVC, caudal to the left renal vein. This model has been widely used by our group for the
study of venous thrombosis.8,17,20,21 It provides reproducible thrombus weights beginning at
3 hours and extending to 21 days, for most mouse strains. It has proven valuable in the study
of interactions between the vein wall and thrombus during the progression from acute to
chronic inflammation and remodeling of the vein wall. Disadvantages include the lack of
blood flow. A technical pitfall unique to this procedure is the potential to induce initial
hypotension. However, compensation by vertebral veins is observed and the survival rate for
this model is around 95%, based on our laboratory’s observations. In addition, the IVC
cannot reopen because of the ligature. This model cannot reproduce the clinical scenario
where a thrombus is nonocclusive, but it can mimic complete occlusion (Figure 2 and
Table). As a guideline, data from our laboratories in C57BL/6 mice shows, approximate
thrombus weights (IVC+thrombus at harvest), of 33 mg at day 2, 29 mg at day 6, and 18 mg
at day 14.
IVC Stenosis Model—This model was initially developed to study early acute thrombosis
and results in a thrombus of similar morphology to the ligation model over time. Currently,
the model is used to study acute and chronic DVT.24,43 In the original description of this
model, a midline incision is performed and the small bowel exteriorized. No branches are
ligated. A neurosurgical vascular clip is applied to the infrarenal IVC for 15 seconds twice,
30 seconds apart to damage the endothelium. A 5-0 Prolene is placed longitudinally along
the ventral surface of the IVC and a 4-0 silk suture is tied around both the IVC and Prolene
suture. The Prolene suture is then removed, allowing blood flow to resume.44 This model
combines external compression with a reduction in blood flow to produce laminar thrombus
at early time points and has been used to study thrombogenesis kinetics and the efficacy of
therapeutic agents.44,45 A modification of this original technique was recently introduced
where no external compression on the IVC is performed, lateral branches are ligated,
posterior branches remain open, and a 7-0 Prolene is tied around the IVC and onto a 30 G
needle. Then the needle is removed creating a ≈90% stenosis.22 Other investigators do not
ligate the lateral branches. A significant disadvantage of this model is the large variation in
the size of the thrombus with an absence of thrombi in some mice. In addition, the thrombus
may lead to complete vessel occlusion. This model is most suited to analyzing the initiation
of thrombosis (Table).
Electrolytic Vein Model—The electrolytic method is an alternative to the stenosis
model.46 The use of electrolysis to generate venous thrombosis in a murine model was first
described by Cooley et al utilizing the femoral vein and who recently characterized a new
model of venous thrombosis.47,48 However, the small size of this vessel and thrombus limit
the sample size for molecular analysis.46 The electrolytic IVC model (EIM) involves the
identical anesthesia and operative approach as the ligation model. Venous side branches are
ligated with 7 to 0 Prolene, but posterior branches remain open. A 25-gauge needle, attached
to a 30-gauge silver-coated copper wire is inserted into the subcutaneous tissue (cathode)
and caudal IVC (anode). A direct current of 25 μAmp is applied over 15 minutes generating
free radicals, which results in endothelial cell activation. A small area of endothelial
denudation was observed at the needle entry point, which can contribute to thrombus
formation. A laminar thrombus is formed with maintenance of a flow channel. Thrombus
weights remain consistent with acceptable standard deviations to detect differences in
experimental groups with a sample size as small as 5 mice, from 6 hours to 14 days post
injury.46,49,50 Importantly, the electrolysis does not affect the intravascular temperature.46,50
This model produces reliable and consistent thrombus weights over a wide range of
endpoints, while also allowing for the study of anti-thrombotic and thrombolytic agents.46
Disadvantages include a longer operative time and damage to the vein wall at the needle
insertion site. The EIM produces thrombi that do not occlude the IVC during acute and
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chronic DVT (unpublished data) because of the constant presence of flow, so it more closely
resembles the clinical scenario where thrombus partially occludes a deep vein. As a
guideline, data from our laboratories in C57BL/6 mice show an average thrombus weight
(IVC+thrombus at harvest) of 15 mg at 2 days, 12 mg at 6 days, and 8 mg at 14 days.
Anatomic Vein Variations in Mice
The vein system in both human and mice varies enormously. The models that used the IVC
to study thrombosis face the problem of what to do with the branches. Lateral and posterior
branches are apparent in the area of the IVC where the thrombus forms. The flow dynamic
within the IVC confers these branches an important role, potentially limiting the size of the
thrombus in formation. In the IVC ligation model, the thrombus grows backwards, from
cranial to caudal, from the ligature to the first open branch (lateral or posterior) and then
stops growing. Thus, the importance of the lateral and posterior branches are critical and
because there are mice with no lateral branches, the only alternative is to standardize the
anatomy by ligating the branches that influence thrombus size. In the EIM model, the
thrombus grows caudal to cranial, following the flow. The importance of the lateral branches
is critical as in the ligation model but not the posterior branches likely because in the EIM
the thrombus remains associated with the anterior wall of the IVC based on our laboratory’s
observations. Thus, in the EIM, the ligation of the side branches is critical and the thrombus
grows until the flow from the renal veins limit the thrombus extension.
Discussion
Animal models of venous thrombosis are necessary in order to understand the mechanisms
of DVT and adequately test pharmaceuticals for treatment of this disease. As an example,
we explored the concept that P-selectin inhibition would help to prevent or treat DVT. We
conducted experiments using mice, rats, and currently baboons to test inhibitors of P-
selectin.8,17,25,51–54 Our findings suggest that blocking P-selectin limits thrombus formation
and accentuates thrombus resolution, protecting the vein wall against fibrosis in all 3
species.8,17,25,51–55
An ideal mouse model of DVT should be technically simple and fast to perform, easily
reproducible, generate a large sample for molecular analysis, form thrombus within a deep
vein, and provide consistent thrombus size. However, there is no ideal “DVT animal model”
due to the simple reason that animals do not develop spontaneous DVT. Thus, investigators
are forced to artificially trigger a thrombus within a vein. In this review we have given a
detailed overview of the advantages and disadvantages of the large vein models of venous
thrombosis. The ferric chloride model enables the study of vein thrombosis from
experiments that can be obtained by simply measuring time to occlusion. The IVC ligation
and stenosis models and the EIM allow the study of actual tissue samples from the area
where vein thrombosis occurs (vein wall and thrombus) and also blood analysis (plasma,
serum). In addition, all 3 models allow the investigation of acute and chronic DVT. The
ligation model, in particular, is useful for studying those clinical scenarios where complete
occlusion and no recanalization occurs causing a severe response in the vein wall. The flow
models (stenosis and EIM) are useful to mimic nonocclusive clinical scenarios, either partial
occlusion and/or recanalization.
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Schematic representation of stasis and flow models through acute venous thrombosis, sub-
acute/chronic venous thrombosis, and chronic venous thrombosis.
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Schematic representation of ligation, stenosis and electrolytic inferior vena cava (IVC)
models. 1 indicates renal veins; 2, infrarenal IVC; 3, iliac veins.
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